Safont MJ et al. - Age is a negative prognostic factor for overall survival (OS) of small-cell lung cancer (SCLC) pts age ≥70 yrs with limited disease (LD); age was also related to a greater dose reduction Methods
Retrospective analysis based on the Spanish Lung Cancer Group (SLCG) clinical trial of high-dose epirubicin/cisplatin in SCLC pts
Study of pts age ≤70 yrs (338 pts) vs ≥70 yrs (64) to evaluate influence of age on response to treatment, toxicity, time to progression (TTP) and OS
Results
Objective responses similar in both groups
TTP was higher in pts age ≤70 yrs vs ≥70 yrs (36 vs 32 wks) and OS was higher (47 vs 42 wks), attributable to improved results in LD subgroup
No significant differences in toxicity profile, except for a higher rate of febrile neutropenia in pts ≥70 yrs with extensive disease (4.6% vs 8.8%)
In LD subgroup, pts ≥70 yrs received less total cisplatin dose (401 vs 508 mg/m2) with less treatment delays reported (10 vs 15 days)
See all
